|
Oct 2
|
AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong
|
|
Sep 30
|
20 Best Residency by Investment Programs in 2023
|
|
Sep 29
|
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
|
|
Sep 28
|
UPDATE 3-J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
|
|
Aug 11
|
Is Most-Watched Stock AstraZeneca PLC (AZN) Worth Betting on Now?
|
|
Aug 10
|
Q2 2023 Ionis Pharmaceuticals Inc Earnings Call
|
|
Aug 9
|
AstraZeneca signs vaccine deal with China’s CanSino
|
|
Aug 9
|
UPDATE 1-China's CanSino in mRNA vaccine deal with AstraZeneca
|
|
Aug 8
|
China's CanSino in mRNA vaccine deal with AstraZeneca
|
|
Aug 8
|
Is This Blue Chip Dividend Stock a Buy for Growth Investors?
|
|
Jun 29
|
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
|
|
Jun 28
|
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
|
|
Jun 28
|
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
|
|
Jun 27
|
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
|
|
Jun 26
|
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
|
|
Jun 26
|
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
|
|
Jun 23
|
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
|
|
Jun 22
|
Is AstraZeneca a Top Stock to Buy Right Now?
|
|
May 25
|
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
|
|
May 24
|
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
|